Acer Therapeutics (NASDAQ:ACER)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Friday. They presently have a $50.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 161.23% from the company’s previous close.
Other research analysts have also issued reports about the stock. Roth Capital initiated coverage on shares of Acer Therapeutics in a research note on Monday, February 26th. They set a “buy” rating and a $70.00 price objective on the stock. William Blair initiated coverage on shares of Acer Therapeutics in a research note on Friday, February 16th. They set an “outperform” rating on the stock. Finally, ValuEngine lowered shares of Acer Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Acer Therapeutics currently has a consensus rating of “Hold” and an average target price of $60.00.
Shares of Acer Therapeutics (ACER) opened at $19.14 on Friday. Acer Therapeutics has a 52 week low of $5.70 and a 52 week high of $22.63. The stock has a market cap of $137.95, a price-to-earnings ratio of -4.92 and a beta of 2.54.
Institutional investors have recently added to or reduced their stakes in the company. Ardsley Advisory Partners acquired a new position in shares of Acer Therapeutics during the 4th quarter worth about $212,000. Stonepine Capital Management LLC acquired a new position in shares of Acer Therapeutics during the 4th quarter worth about $1,385,000. J. Goldman & Co LP acquired a new position in shares of Acer Therapeutics during the 4th quarter worth about $1,496,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Acer Therapeutics during the 4th quarter worth about $2,091,000. Institutional investors own 7.54% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3250344/hc-wainwright-reaffirms-buy-rating-for-acer-therapeutics-acer.html.
About Acer Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.